AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01769391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study NCT01769391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered IV
Study NCT00329979 — intervention group
Intervention type: BEHAVIORAL
Intervention: vascular access site
Description: Randomized vascular access site
Study NCT03386929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
Study NCT03386929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
Study NCT03386929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
Study NCT03076450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Adjust PEEP real-time in term of LUS-RAS chang.
Study NCT03076450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximum Oxygenation
Description: Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
Study NCT00258518 — intervention group
Intervention type: PROCEDURE
Intervention: mechanical ventilation/CT Scan
Description: evaluation of pleural effusion and respiratory mechanics, CT scan
Study NCT06015594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients treated with metformin
Study NCT04084769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: IM
Study NCT04084769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B vaccine (Trumenba®)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT04084769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B vaccine (Bexsero®)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT05486754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management
Description: Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
Study NCT05486754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Control
Description: Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
Study NCT04274751 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation
Study NCT01247558 — intervention group
Intervention type: OTHER
Intervention: Metanx® (a medical food)
Description: Patient cohort compliant on Metanx® BID therapy for >120 days
Study NCT01247558 — intervention group
Intervention type: OTHER
Intervention: Not treated with Metanx®
Description: Non-treated comparative cohort
Study NCT03538054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: (1)10 mg, by mouth, twice daily every 12 hours.
Study NCT00815698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture
Description: suture for mesh fixation
Study NCT00815698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no suture
Description: no suture for mesh fixation, because we use a self-adhesive mesh
Study NCT00412542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg PO (by mouth) daily for 8 weeks
Study NCT00412542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
Study NCT00412542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Dynamic MRI scan with dye injection through vein, every 6 weeks
Study NCT00412542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Tests (QST)
Description: QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
Study NCT03538054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule, by mouth, twice daily every 12 hours.
Study NCT03650322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 weeks, total of 150 minutes of exercise per week.
Study NCT03650322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Toning
Description: 12 weeks, total of 150 minutes of exercise per week.
Study NCT03650322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Walking
Description: 12 weeks, total of 150 minutes of exercise per week.
Study NCT03083405 — intervention group
Intervention type: DRUG
Intervention: Opipramol
Description: The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
Study NCT01976195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days
Study NCT01976195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days
Study NCT01976195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 150mg per day, 15 consecutive days
Study NCT02550262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Study NCT02759029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eradication of Helicobacter pylori
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk
Study NCT02759029 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: eradication of Helicobacter pylori
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk
Study NCT03314584 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Description: Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
Study NCT02672813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral nerve I and II block
Description: Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
Study NCT03543839 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
Study NCT03543839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab/Placebo
Description: Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
Study NCT03543839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
Study NCT00673296 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Bevacizumab
Description: Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
Study NCT00731211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg of pazopanib orally each day continuously
Study NCT03429855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk training
Description: Bobath based trunk training
Study NCT03429855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: conventional physiotherapy
Study NCT04018118 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological sample
Description: Additional blood samples for biobanking
Study NCT03603717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
Study NCT03603717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
Study NCT01670110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide LAR
Description: Injectible, 60mg per month
Study NCT01670110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To be injected once per month
Study NCT05678296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
Study NCT05678296 — intervention group
Intervention type: DRUG
Intervention: Analgesic
Description: Analgesics are prescribed for the patients for all groups.
Study NCT05678296 — intervention group
Intervention type: PROCEDURE
Intervention: traditional osteotomies
Description: In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
Study NCT05678296 — intervention group
Intervention type: BIOLOGICAL
Intervention: Platelet Rich Fibrin
Description: Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
Study NCT05678296 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: no systemic antibiotics are prescribed for the patients for all groups.
Study NCT02741167 — intervention group
Intervention type: PROCEDURE
Intervention: CRS and HIPEC
Description: During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
Study NCT03438487 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flucelvax Trivalent Influenza Vaccine
Description: Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)
Study NCT03438487 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flucelvax Quadrivalent Influenza Vaccine
Description: Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)
Study NCT02841891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sylys® Surgical Sealant
Description: Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
Study NCT02841891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled Anastomosis Colectomy Procedure
Description: Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
Study NCT01372163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
Study NCT01372163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
Study NCT01372163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457 or Placebo
Description: Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
Study NCT00966199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-hypertensive medication
Description: 8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
Study NCT02279342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
Study NCT01560949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
Study NCT01560949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
Study NCT03499951 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wheelchair Skills Training - Remote
Description: Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
Study NCT03499951 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wheelchair Skills Training - In Person
Description: Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
Study NCT03807739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F09 Formulation
Description: Participants will receive a single oral dose of GDC-0134 reference capsule F09.
Study NCT03807739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F15 Formulation
Description: Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
Study NCT03807739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0134 F16 Formulation
Description: Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
Study NCT00875017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Description: 1 x 1000mg tablet
Study NCT00875017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: 3 x 800mg tablets
Study NCT02550262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Study NCT02550262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study NCT01560949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
Study NCT01560949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
Study NCT01560949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
Study NCT02132702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study NCT02833350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
Study NCT01996735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180 mg single dose
Study NCT02730767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: partially supervised exercise intervention
Study NCT02043717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism \[Internet\]. 2012 May \[cited 2012 Oct 31\];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505
Study NCT04231474 — intervention group
Intervention type: DEVICE
Intervention: Urodynamic testing
Description: All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
Study NCT01996735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05187806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
Study NCT02238028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wear respirator
Description: Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
Study NCT01303835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDN
Description: Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
Study NCT01303835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized patients received placebo to be taken every night before bed.
Study NCT03067051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
Study NCT03067051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpectraCure P18 System
Description: Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
Study NCT02299921 — intervention group
Intervention type: OTHER
Intervention: Characterize alcohol and drug use
Description: Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.